These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. Marathe A; Krzyzanski W; Mager DE J Pharmacokinet Pharmacodyn; 2009 Jun; 36(3):199-219. PubMed ID: 19434483 [TBL] [Abstract][Full Text] [Related]
24. Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon-γ-Induced Protein 10, BMS-986184, in Healthy Participants to Guide Therapeutic Dosing. Cai W; Leil TA; Gibiansky L; Krishna M; Zhang H; Gu H; Sun H; Throup J; Banerjee S; Girgis I Clin Pharmacol Drug Dev; 2020 Aug; 9(6):689-698. PubMed ID: 32068354 [TBL] [Abstract][Full Text] [Related]
25. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Gibiansky L; Gibiansky E Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):803-12. PubMed ID: 19505189 [TBL] [Abstract][Full Text] [Related]
27. Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor. Yan X; Chen Y; Krzyzanski W J Pharmacokinet Pharmacodyn; 2012 Oct; 39(5):543-60. PubMed ID: 22926955 [TBL] [Abstract][Full Text] [Related]
28. Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model. Ternant D; Le Tilly O; Picon L; Moussata D; Passot C; Bejan-Angoulvant T; Desvignes C; Mulleman D; Goupille P; Paintaud G Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834236 [TBL] [Abstract][Full Text] [Related]
29. Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Minireview. An G J Clin Pharmacol; 2017 Feb; 57(2):137-150. PubMed ID: 27489162 [TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamic-Mediated Drug Disposition (PDMDD) Model of Daratumumab Monotherapy in Patients with Multiple Myeloma. Li X; Dosne AG; Pérez Ruixo C; Perez Ruixo JJ Clin Pharmacokinet; 2023 May; 62(5):761-777. PubMed ID: 37022569 [TBL] [Abstract][Full Text] [Related]
31. Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. Grimm HP J Pharmacokinet Pharmacodyn; 2009 Oct; 36(5):407-20. PubMed ID: 19728050 [TBL] [Abstract][Full Text] [Related]
32. Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys. Vexler V; Yu L; Pamulapati C; Garrido R; Grimm HP; Sriraman P; Bohini S; Schraeml M; Singh U; Brandt M; Ries S; Ma H; Klumpp K; Ji C MAbs; 2013; 5(5):776-86. PubMed ID: 23924796 [TBL] [Abstract][Full Text] [Related]
33. Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds. An G J Clin Pharmacol; 2020 Feb; 60(2):149-163. PubMed ID: 31793004 [TBL] [Abstract][Full Text] [Related]
34. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Mager DE; Krzyzanski W Pharm Res; 2005 Oct; 22(10):1589-96. PubMed ID: 16180117 [TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model. Xin Y; Xiang H; Jin D; Theil FP; Joshi A; Damico-Beyer LA; Bai S J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):217-26. PubMed ID: 22382554 [TBL] [Abstract][Full Text] [Related]
36. Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification. Peletier LA; Gabrielsson J J Pharmacokinet Pharmacodyn; 2012 Oct; 39(5):429-51. PubMed ID: 22851162 [TBL] [Abstract][Full Text] [Related]
37. General Pharmacokinetic Features of Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Simulation-Based Study. Bach T; Jiang Y; Zhang X; An G J Clin Pharmacol; 2019 Mar; 59(3):394-405. PubMed ID: 30387863 [TBL] [Abstract][Full Text] [Related]
38. Target-mediated drug disposition and dynamics. Mager DE Biochem Pharmacol; 2006 Jun; 72(1):1-10. PubMed ID: 16469301 [TBL] [Abstract][Full Text] [Related]
39. Target-Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy. Schropp J; Khot A; Shah DK; Koch G CPT Pharmacometrics Syst Pharmacol; 2019 Mar; 8(3):177-187. PubMed ID: 30480383 [TBL] [Abstract][Full Text] [Related]
40. Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition. Marathe A; Van Wart S; Mager DE J Pharmacokinet Pharmacodyn; 2011 Apr; 38(2):223-35. PubMed ID: 21165681 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]